Leukolysins and Cancer

  • Janet H. Ransom
  • John R. Ortaldo

Part of the Contemporary Biomedicine book series (CB, volume 8)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Biology and Biochemistry

    1. Front Matter
      Pages 1-1
    2. Janet H. Ransom, John R. Ortaldo
      Pages 3-8
    3. John Ding-E Young, Chau-Ching Liu, Lauren G. Leong, Angela Damiano, Marie A. Dinome, Zanvil A. Cohn
      Pages 9-43
    4. Craig W. Reynolds, Pierre Henkart
      Pages 45-63
    5. Hillel S. Koren, Karen P. McKinnon, Allen R. Chen
      Pages 67-86
    6. Paul Aebersold
      Pages 101-117
    7. Natural Killer Cell Cytotoxic Factor

      1. Susan C. Wright, Benjamin Bonavida
        Pages 121-135
      2. John R. Ortaldo
        Pages 137-147
      3. Richard L. Deem, Stephan R. Targan
        Pages 149-165
    8. Leukoregulin

      1. Janet H. Ransom, Randall E. Merchant
        Pages 169-187
      2. Charles H. Evans
        Pages 189-215
      3. Robert S. Yamamoto, Bruce J. Averbook, Mary T. Fitzgerald, Irene K. Masunaka, Sally L. Orr, Gale A. Granger
        Pages 217-234
      4. Michael A. Palladino Jr., Arthur J. Ammann
        Pages 235-244
  3. Clinical Applications

    1. Front Matter
      Pages 245-245
    2. Interferons

      1. Mark S. Roth, Kenneth A. Foon
        Pages 247-271
      2. Joan H. Schiller, Ernest C. Borden
        Pages 273-302
      3. Arthur J. Ammann, Michael A. Palladino Jr.
        Pages 303-311
      4. Janet H. Ransom, Linda S. Cleveland
        Pages 313-317
  4. Back Matter
    Pages 319-322

About this book


Regulation of malignant cell growth by the immune system has been extensively studied by cancer researchers hoping to develop immuno­ therapeutic approaches to cancer management. For years these studies revolved around the recognition and destruction of tumors by cytotox. ic immune effector cells. Recently, however, attention has focused on the leukolysins, which are the soluble cytotoxic molecules secreted by activated leukocytes, because of their anticancer activities. The purpose of this book is to give an overview of the ieukolysins, with emphasis on their ability to regulate malignant cell growth. Because this is such a new field in cancer research, there remains some confusion regarding the tenninology of. and biological activity ascribed to, the different leukolysins. Therefore, we sought to present a comprehensive review of the leukolysins currently under intensive study and to compare and contrast their biological activities in an attempt to clarify the nature of these diverse biological species. This book is intended for both immunologists conducting basic research and clinical oncologists, since it reviews not only the clinical applications of the leukolysins, but presents a current update on those leukolysins that are in early developmental stages of research and could enter into clinical trials in a few years. The introduction gives an overview of the status of research on the leukolysins. In the first section, the biological activities and biochemical characteristics of the leukolysins are presented. The lymphokines.


TNF carcinoma cell clinical trial cytokines hyperthermia interferon leukemia lymphocytes lymphoma melanoma molecular biology oncogene renal cell carcinoma tumor

Editors and affiliations

  • Janet H. Ransom
    • 1
  • John R. Ortaldo
    • 2
  1. 1.Bionetics Research Inc.RockvilleUSA
  2. 2.Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer TreatmenNational Cancer Institute, Frederick Cancer Research FacilityFrederickUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology